Kava in the treatment of generalized anxiety disorder: A double-blind, randomized, placebo-controlled study

Journal of Clinical Psychopharmacology

Volumn 33, Issue 5, 2013, Pages 643-648

  Sarris, Jerome ^a   Stough, Con ^a   Bousman, Chad A ^a   Wahid, Zahra T ^a   Murray, Greg ^a   Teschke, Rolf ^a   Savage, Karen M ^a   Dowell, Ashley ^a   Ng, Chee ^a   Schweitzer, Isaac ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID CARRIER; KAVA EXTRACT; NORADRENALIN TRANSPORTER;

ADULT; ALLELE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DERMATITIS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENERALIZED ANXIETY DISORDER; GENETIC ASSOCIATION; GENETIC MARKER; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PIPER METHYSTICUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH DISCOMFORT; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; FEMALE; GABA PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; KAVA; MALE; PHARMACOGENETICS; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; TREATMENT OUTCOME; VICTORIA; YOUNG ADULT;

EID: 84883757118     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318291be67     Document Type: Article

References (34)

1. Hidalgo RB, Tupler LA, Davidson Jr. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol. 2007;21(8):864-872
2. Amsterdam JD, Li Y, Soeller I, et al. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. J Clin Psychopharmacol. 2009;29(4):378-382
3. Sarris J, LaPorte E, Schweitzer I. Kava: A comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry. 2011;45(1):27-35
4. LaPorte E, Sarris J, Stough C, et al. Neurocognitive effects of kava (Piper methysticum): A systematic review. Hum Psychopharmacol. 2011;26(2):102-111
5. Magura EI, Kopanitsa MV, Gleitz J, et al. Kava extract ingredients, (+)-methysticin and (+/j)-kavain inhibit voltage-operated Na(+)-channels in rat CA1 hippocampal neurons. Neuroscience. 1997;81(2):345-351
6. Gleitz J, Beile A, Peters T. (+/-)-Kavain inhibits veratridine-Activated voltage-dependent Na(+)-channels in synaptosomes prepared from rat cerebral cortex. Neuropharmacology. 1995;34(9):1133-1138
7. Martin HB, McCallum M, Stofer WD, et al. Kavain attenuates vascular contractility through inhibition of calcium channels. Planta Med. 2002;68(9):784-789
8. Walden J, von Wegerer J, Winter U, et al. Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. Prog Neuropsychopharmacol Biol Psychiatry. 1997;21(4):697-706
9. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology (Berl). 1994;116(4):469-474
10. Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava). Pharmacopsychiatry. 1998;31(5):187-192
11. Wu D, Yu L, Nair M, et al. Cyclooxygenase enzyme inhibitory compounds with antioxidant activities from Piper methysticum (kava kava) roots. Phytomedicine. 2002;9:41-47
12. Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22(7):1105-1120
13. Seitz U, Schule A, Gleitz J. [3H]-monoamine uptake inhibition properties of kava pyrones. Planta Med. 1997;63(6):548-549
14. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev. 2003;(1):CD003383
15. Sarris J, Kavanagh D, Byrne G, et al. The Kava Anxiety Depression Spectrum Study (KADSS): A randomized, placebo-controlled, cross-over trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl). 2009;205(3):399-407
16. Connor KM, Payne V, Davidson Jr. Kava in generalized anxiety disorder: Three placebo-controlled trials. Int Clin Psychopharmacol. 2006;21(5):249-253
17. Grunze H, Langosch J, Schirrmacher K, et al. Kava pyrones exert effects on neuronal transmission and transmembraneous cation currents similar to established mood stabilizersVa review. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25(8):1555-1570
18. Sarris J, Scholey A, Schweitzer I, et al. The acute effects of kava and oxazepam on anxiety, mood, neurocognition, and genetic correlates: A randomized, placebo-controlled, double-blind study. Human Psychopharm. 2012;27(3):262-269
19. Thoeringer CK, Ripke S, Unschuld PG, et al. The GABA transporter 1 (SLC6A1): A novel candidate gene for anxiety disorders. J Neural Transm. 2009;116(6):649-657
20. Tiwari AK, Souza RP, Muller DJ. Pharmacogenetics of anxiolytic drugs. J Neural Transm. 2009;116(6):667-677
21. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55
22. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol. 1988; 56:893-897
23. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389
24. Knight J. Liver function tests: Their role in the diagnosis of hepatobiliary diseases. J Infus Nurs. 2005;28:108-117
25. Sarris J, Ng C, Schweitzer I. Omic genetic technologies for herbal medicines in psychiatry. Phytother Res. 2012;26(4):522-527
26. Morris S. Estimating effect sizes from pretest-posttest-control group designs. Organizational Research Methods. 2008;11(2):364-386
27. Sarris J, Teschke R, Stough C, et al. Re-introduction of kava (Piper methysticum) to the EU: Is there a way forward? Planta Med. 2011;77(2):107-110
28. Sarris J, Stough C, Teschke R, et al. Kava for the treatment of generalized anxiety disorder RCT: Analysis of adverse reactions, liver function, addiction, and sexual effects. Phytother Res. 2013. In press
29. Clouatre DL. Kava kava: Examining new reports of toxicity. Toxicol Lett. 2004;150(1):85-96
30. Bauer R. Relevant hepatotoxicity effects of kava still need to be proven. Planta Med. 2003;69:971-972
31. Coulter D. Assessment of the risk of hepatotoxicity with kava products. WHO appointed committee 2007
32. Teschke R, Genthner A, Wolff A. Kava hepatotoxicity: Comparison of aqueous, ethanolic, acetonic kava extracts and kava-herbs mixtures. J Ethnopharmacol. 2009;123(3):378-384
33. Teschke R. Kava hepatotoxicityVa clinical review. Ann Hepatol. 2010; 9:9:251-265
34. Teschke R, Sarris J, Schweitzer I. Kava hepatotoxicity in traditional and modern use: The presumed Pacific kava paradox hypothesis revisited. Br J Clin Pharmacol. 2012;73(2):170-174